omnicell inc. - OMCL
OMCL
Close Chg Chg %
38.61 0.02 0.05%
Closed Market
38.63
+0.02 (0.05%)
Volume: 592.28K
Last Updated:
Feb 19, 2026, 4:00 PM EDT
Company Overview: omnicell inc. - OMCL
OMCL Key Data
| Open $38.13 | Day Range 37.60 - 38.87 |
| 52 Week Range 22.66 - 55.00 | Market Cap $1.64B |
| Shares Outstanding 44.88M | Public Float 43.52M |
| Beta 0.78 | Rev. Per Employee N/A |
| P/E Ratio 871.56 | EPS $0.04 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 777.63K |
OMCL Performance
| 1 Week | 5.84% | ||
| 1 Month | -23.54% | ||
| 3 Months | 7.31% | ||
| 1 Year | -2.74% | ||
| 5 Years | -70.50% |
OMCL Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
8
Full Ratings ➔
About omnicell inc. - OMCL
Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Fort Worth, TX.
OMCL At a Glance
Omnicell, Inc.
4220 North Freeway
Fort Worth, Texas 76137
| Phone | 1-877-415-9990 | Revenue | 1.18B | |
| Industry | Information Technology Services | Net Income | 2.05M | |
| Sector | Technology Services | 2025 Sales Growth | 6.528% | |
| Fiscal Year-end | 12 / 2026 | Employees | N/A | |
| View SEC Filings |
OMCL Valuation
| P/E Current | 871.558 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 1,022.573 |
| Price to Sales Ratio | 1.773 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | 16.50 |
| Enterprise Value to EBITDA | 24.317 |
| Enterprise Value to Sales | 1.723 |
| Total Debt to Enterprise Value | 0.094 |
OMCL Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | 5.464 |
| Total Asset Turnover | 0.579 |
OMCL Liquidity
| Current Ratio | 1.427 |
| Quick Ratio | 1.215 |
| Cash Ratio | 0.527 |
OMCL Profitability
| Gross Margin | 42.49 |
| Operating Margin | 0.436 |
| Pretax Margin | 0.956 |
| Net Margin | 0.173 |
| Return on Assets | 0.10 |
| Return on Equity | 0.166 |
| Return on Total Capital | 0.144 |
| Return on Invested Capital | 0.143 |
OMCL Capital Structure
| Total Debt to Total Equity | 15.618 |
| Total Debt to Total Capital | 13.509 |
| Total Debt to Total Assets | 9.743 |
| Long-Term Debt to Equity | 15.618 |
| Long-Term Debt to Total Capital | 13.509 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Omnicell Inc. - OMCL
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 1.30B | 1.15B | 1.11B | 1.18B | |
Sales Growth
| +14.48% | -11.48% | -3.04% | +6.53% | |
Cost of Goods Sold (COGS) incl D&A
| 698.94M | 647.18M | 636.73M | 681.40M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 99.17M | 95.56M | 89.75M | 78.80M | |
Depreciation
| - | 63.97M | 63.96M | 42.02M | |
Amortization of Intangibles
| - | 35.20M | 31.60M | 47.73M | |
COGS Growth
| +21.14% | -7.41% | -1.61% | +7.02% | |
Gross Income
| 597.00M | 499.93M | 475.51M | 503.44M | |
Gross Income Growth
| +7.56% | -16.26% | -4.89% | +5.87% | |
Gross Profit Margin
| +46.07% | +43.58% | +42.75% | +42.49% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 576.52M | 519.26M | 470.02M | 498.28M | |
Research & Development
| 101.35M | 93.29M | 89.99M | 88.67M | |
Other SG&A
| 475.17M | 425.97M | 380.02M | 409.61M | |
SGA Growth
| +27.32% | -9.93% | -9.48% | +6.01% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | 22.80M | 15.54M | (2.36M) | |
EBIT after Unusual Expense
| (2.32M) | (34.87M) | 7.85M | 5.16M | |
Non Operating Income/Expense
| 4.37M | 19.29M | 22.26M | 6.17M | |
Non-Operating Interest Income
| - | - | 24.90M | 6.17M | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | 4.50M | 4.53M | 4.53M | |
Interest Expense Growth
| - | -79.88% | +0.56% | -0.09% | |
Gross Interest Expense
| - | 4.50M | 4.53M | 4.53M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (2.45M) | (20.11M) | 25.59M | 11.32M | |
Pretax Income Growth
| -103.72% | -719.73% | +227.28% | -55.75% | |
Pretax Margin
| -0.19% | -1.75% | +2.30% | +0.96% | |
Income Tax
| (8.10M) | 263.00K | 13.06M | 9.27M | |
Income Tax - Current - Domestic
| - | 26.00M | 10.03M | 26.77M | |
Income Tax - Current - Foreign
| - | 192.00K | 840.00K | 846.00K | |
Income Tax - Deferred - Domestic
| - | (33.73M) | (10.26M) | (14.30M) | |
Income Tax - Deferred - Foreign
| - | (561.00K) | (341.00K) | (252.00K) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 5.65M | (20.37M) | 12.53M | 2.05M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 5.65M | (20.37M) | 12.53M | 2.05M | |
Net Income Growth
| -92.74% | -460.68% | +161.51% | -83.62% | |
Net Margin Growth
| +0.44% | -1.78% | +1.13% | +0.17% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 5.65M | (20.37M) | 12.53M | 2.05M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 5.65M | (20.37M) | 12.53M | 2.05M | |
EPS (Basic)
| 0.1272 | -0.4506 | 0.2721 | 0.0446 | |
EPS (Basic) Growth
| -92.90% | -454.25% | +160.39% | -83.61% | |
Basic Shares Outstanding
| 44.40M | 45.21M | 46.05M | 45.97M | |
EPS (Diluted)
| 0.1231 | -0.4506 | 0.2709 | 0.0443 | |
EPS (Diluted) Growth
| -92.42% | -466.04% | +160.12% | -83.65% | |
Diluted Shares Outstanding
| 45.89M | 45.21M | 46.26M | 46.36M | |
EBITDA
| 119.65M | 76.23M | 95.25M | 83.95M | |
EBITDA Growth
| -36.07% | -36.29% | +24.95% | -11.85% | |
EBITDA Margin
| +9.23% | +6.65% | +8.56% | +7.09% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 58.857 | |
| Number of Ratings | 8 | Current Quarters Estimate | 0.326 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | 1.746 | |
| Last Quarter’s Earnings | 0.40 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 1.62 | Next Fiscal Year Estimate | 2.099 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 8 | 8 | 8 | 7 |
| Mean Estimate | 0.33 | 0.42 | 1.75 | 2.10 |
| High Estimates | 0.35 | 0.47 | 1.84 | 2.58 |
| Low Estimate | 0.29 | 0.38 | 1.66 | 1.88 |
| Coefficient of Variance | 7.13 | 7.40 | 3.44 | 11.26 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 7 | 6 | 5 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 1 | 2 | 3 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Overweight | Overweight |
SEC Filings for Omnicell Inc. - OMCL
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Omnicell Inc. - OMCL
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jan 13, 2026 | Corey J. Manley EVP&CHIEF LEGAL/ADMIN OFFICER | 91,674 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $49.9 per share | 4,574,532.60 |
| Dec 4, 2025 | Randall A. Lipps CHAIRMAN, PRESIDENT AND CEO; Director | 414,898 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $27.7 per share | 11,492,674.60 |
| Dec 4, 2025 | Randall A. Lipps CHAIRMAN, PRESIDENT AND CEO; Director | 386,648 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $35.97 per share | 13,907,728.56 |
| Dec 4, 2025 | Randall A. Lipps CHAIRMAN, PRESIDENT AND CEO; Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 20, 2025 | Randall A. Lipps CHAIRMAN, PRESIDENT AND CEO; Director | 404,669 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $28.08 per share | 11,363,105.52 |
| May 20, 2025 | Brian H. Nutt VP, Chief Accounting Officer | 9,955 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $28.08 per share | 279,536.40 |
| May 20, 2025 | Nchacha E. Etta EVP & CFO | 128,497 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $28.08 per share | 3,608,195.76 |
| Mar 12, 2025 | Randall A. Lipps CHAIRMAN, PRESIDENT AND CEO; Director | 323,049 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $36.99 per share | 11,949,582.51 |
| Mar 12, 2025 | Nchacha E. Etta EVP & CFO | 132,023 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $36.99 per share | 4,883,530.77 |
| Mar 12, 2025 | Corey J. Manley EVP&CHIEF LEGAL/ADMIN OFFICER | 97,907 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $36.99 per share | 3,621,579.93 |